JP2015505818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505818A5 JP2015505818A5 JP2014541396A JP2014541396A JP2015505818A5 JP 2015505818 A5 JP2015505818 A5 JP 2015505818A5 JP 2014541396 A JP2014541396 A JP 2014541396A JP 2014541396 A JP2014541396 A JP 2014541396A JP 2015505818 A5 JP2015505818 A5 JP 2015505818A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- fgfr1
- therapeutic agent
- agent according
- ecd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124597 therapeutic agent Drugs 0.000 claims 37
- 239000012830 cancer therapeutic Substances 0.000 claims 35
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 32
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 29
- 101150016624 fgfr1 gene Proteins 0.000 claims 29
- 238000000034 method Methods 0.000 claims 25
- 230000004927 fusion Effects 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 14
- 230000004544 DNA amplification Effects 0.000 claims 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 10
- 201000005202 lung cancer Diseases 0.000 claims 10
- 208000020816 lung neoplasm Diseases 0.000 claims 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 210000002230 centromere Anatomy 0.000 claims 8
- 210000000349 chromosome Anatomy 0.000 claims 8
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 230000002018 overexpression Effects 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 6
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 6
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 claims 6
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 claims 6
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 6
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 claims 6
- 102000048850 Neoplasm Genes Human genes 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- -1 FGFR3IIIc Proteins 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 238000000018 DNA microarray Methods 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 238000002105 Southern blotting Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 238000007901 in situ hybridization Methods 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 230000003595 spectral effect Effects 0.000 claims 2
- 230000004797 therapeutic response Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 description 3
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559259P | 2011-11-14 | 2011-11-14 | |
| US61/559,259 | 2011-11-14 | ||
| US201261616761P | 2012-03-28 | 2012-03-28 | |
| US61/616,761 | 2012-03-28 | ||
| PCT/US2012/064772 WO2013074492A1 (en) | 2011-11-14 | 2012-11-13 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091502A Division JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505818A JP2015505818A (ja) | 2015-02-26 |
| JP2015505818A5 true JP2015505818A5 (OSRAM) | 2017-01-05 |
Family
ID=48430074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541396A Pending JP2015505818A (ja) | 2011-11-14 | 2012-11-13 | 癌を治療する方法 |
| JP2017091502A Active JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091502A Active JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10016484B2 (OSRAM) |
| EP (1) | EP2780033B1 (OSRAM) |
| JP (2) | JP2015505818A (OSRAM) |
| CN (2) | CN104168915A (OSRAM) |
| AU (1) | AU2012318247B2 (OSRAM) |
| CA (1) | CA2855818A1 (OSRAM) |
| HK (2) | HK1202240A1 (OSRAM) |
| TW (1) | TW201326201A (OSRAM) |
| WO (1) | WO2013074492A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| BRPI0916904A2 (pt) | 2008-08-04 | 2016-10-11 | Fiveprime Therapeutics Inc | polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos |
| PL2498799T3 (pl) | 2009-11-13 | 2017-03-31 | Five Prime Therapeutics, Inc. | Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| US10016484B2 (en) | 2011-11-14 | 2018-07-10 | Five Prime Therapeutics, Inc. | Methods of treating lung cancer |
| TWI726291B (zh) | 2013-01-07 | 2021-05-01 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| US20160067307A1 (en) * | 2013-05-01 | 2016-03-10 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| US10877024B2 (en) * | 2015-05-12 | 2020-12-29 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
| CN107794293A (zh) * | 2016-08-31 | 2018-03-13 | 安诺优达基因科技(北京)有限公司 | 一种基因捕获试剂盒 |
| CN109609640A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院上海高等研究院 | Etv4的用途 |
| AU2019460208A1 (en) * | 2019-08-05 | 2022-03-17 | Genex Health Co., Ltd | Method for culturing primary cells of lung cancer solid tumor and primary tumor cells of lung cancer pleural effusion, and supporting reagent |
| CN111735950B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Fgf18和ca125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN111912987B (zh) * | 2020-08-25 | 2023-07-21 | 北京信诺卫康科技有限公司 | Fgf18和he4联合用作早期卵巢癌生物标志物以及试剂盒 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486462A (en) | 1984-11-23 | 1996-01-23 | The Regents Of The University Of California | Differentiative expression modules |
| US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| GB9001466D0 (en) | 1990-01-23 | 1990-03-21 | Erba Carlo Spa | Extracellular form of the human fibroblast growth factor receptor |
| DK0481000T3 (da) | 1989-07-06 | 1999-11-15 | Univ California | Receptorer for fibroblastvækstfaktorer |
| US5750371A (en) | 1990-04-27 | 1998-05-12 | Takeda Chemical Industries Ltd | Water-soluble mutein of FGF receptor, DNA and production thereof |
| AU662107B2 (en) | 1990-07-06 | 1995-08-24 | Aventis Pharmaceuticals Inc. | Fibroblast growth factor receptors |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| US5229501A (en) * | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
| IL100219A0 (en) | 1991-12-02 | 1992-09-06 | Yeda Res & Dev | Variable region within fibroblast growth factor receptors that confers ligand specificity |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US6517872B1 (en) | 1995-06-12 | 2003-02-11 | Yeda Research And Development Co., Ltd. | FGFR3 as a marker for mesenchymal skeletal progenitor cells |
| AU3494397A (en) | 1996-06-18 | 1998-01-07 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fibroblast growth factor receptor activating gene i and related compositions and methods |
| DE19802377A1 (de) | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
| US6656728B1 (en) * | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| DE60234202D1 (de) | 2001-05-24 | 2009-12-10 | Zymogenetics Inc | Taci-immunoglobulin-fusionsproteine |
| WO2003038054A2 (en) | 2001-10-31 | 2003-05-08 | New York University | Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds |
| CA2492267C (en) | 2002-07-15 | 2013-09-10 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| CA2550245A1 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| JP2008506366A (ja) | 2004-05-14 | 2008-03-06 | レセプター バイオロジックス インコーポレイテッド | 細胞表面受容体アイソフォームならびにその同定および使用方法 |
| EP1773305A2 (en) | 2004-05-25 | 2007-04-18 | Yale University Corporation | Method for treating skeletal disorders resulting from fgfr malfunction |
| CA2589895A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| WO2007059574A1 (en) | 2005-11-23 | 2007-05-31 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| CA2637988A1 (en) | 2006-02-10 | 2007-11-29 | Genentech, Inc. | Anti-fgf19 antibodies and methods using same |
| WO2007134210A2 (en) | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
| AR063975A1 (es) * | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| WO2008103755A1 (en) | 2007-02-20 | 2008-08-28 | Mayo Foundation For Medical Education And Research | Treating cancer with viral nucleic acid |
| AU2008230880B2 (en) | 2007-03-23 | 2014-04-24 | The Translational Genomics Research Institute | Method of diagnosing, classifying and treating endometrial cancer and precancer |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| CL2008003449A1 (es) | 2007-11-21 | 2010-02-19 | Imclone Llc | Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer. |
| MX342553B (es) | 2008-04-29 | 2016-10-04 | Novartis Ag | Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos. |
| BRPI0916904A2 (pt) | 2008-08-04 | 2016-10-11 | Fiveprime Therapeutics Inc | polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos |
| EP2478003A4 (en) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4 |
| PL2498799T3 (pl) | 2009-11-13 | 2017-03-31 | Five Prime Therapeutics, Inc. | Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2 |
| US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
| CN107050426A (zh) | 2010-11-15 | 2017-08-18 | 戊瑞治疗有限公司 | Fgfr1胞外域组合疗法 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| IT1404531B1 (it) | 2011-02-24 | 2013-11-22 | Sisvel Technology Srl | Procedimento e sistema di localizzazione indoor per terminali mobili in una rete di telecomunicazione mobile cellulare e relativo terminale mobile. |
| AU2012229107A1 (en) | 2011-03-17 | 2013-09-19 | Novartis Ag | FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects |
| EP2723391B1 (en) | 2011-06-24 | 2018-06-13 | University of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| US10016484B2 (en) | 2011-11-14 | 2018-07-10 | Five Prime Therapeutics, Inc. | Methods of treating lung cancer |
| US20160067307A1 (en) | 2013-05-01 | 2016-03-10 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
-
2012
- 2012-11-13 US US14/357,336 patent/US10016484B2/en active Active
- 2012-11-13 CN CN201280066268.4A patent/CN104168915A/zh active Pending
- 2012-11-13 CN CN201711171931.8A patent/CN107823630A/zh active Pending
- 2012-11-13 HK HK15102726.0A patent/HK1202240A1/xx unknown
- 2012-11-13 CA CA2855818A patent/CA2855818A1/en not_active Abandoned
- 2012-11-13 EP EP12849489.5A patent/EP2780033B1/en active Active
- 2012-11-13 JP JP2014541396A patent/JP2015505818A/ja active Pending
- 2012-11-13 TW TW101142331A patent/TW201326201A/zh unknown
- 2012-11-13 US US13/675,255 patent/US20130136740A1/en not_active Abandoned
- 2012-11-13 WO PCT/US2012/064772 patent/WO2013074492A1/en not_active Ceased
- 2012-11-13 HK HK15102035.6A patent/HK1201462A1/xx unknown
- 2012-11-13 AU AU2012318247A patent/AU2012318247B2/en active Active
-
2017
- 2017-05-02 JP JP2017091502A patent/JP6578318B2/ja active Active
-
2018
- 2018-06-08 US US16/003,590 patent/US10537611B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505818A5 (OSRAM) | ||
| Yau | Precision treatment in colorectal cancer: Now and the future | |
| Wang et al. | Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers | |
| Kim et al. | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma | |
| Ross et al. | Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations | |
| Smith et al. | Strategies for modern biomarker and drug development in oncology | |
| Pietrantonio et al. | A review on biomarkers for prediction of treatment outcome in gastric cancer | |
| Shaib et al. | Markers of resistance to anti-EGFR therapy in colorectal cancer | |
| ES2661238T3 (es) | Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer | |
| Knapp et al. | Recently targeted kinases and their inhibitors—the path to clinical trials | |
| Ting et al. | ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma | |
| Kim et al. | Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion | |
| US20140134158A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
| Guo et al. | L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival | |
| Capdevila et al. | Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets | |
| Yu et al. | VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer | |
| Chiang et al. | Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas | |
| JP2016526016A5 (OSRAM) | ||
| Fang et al. | The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells | |
| RU2015150233A (ru) | Способы лечения злокачественной опухоли | |
| US20140030257A1 (en) | Agtr1 as a marker for bevacizumab combination therapies | |
| Kim et al. | Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma | |
| Lee et al. | Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy | |
| Wang et al. | FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma | |
| Choi et al. | Mutational and expressional analysis of ERBB 3 gene in common solid cancers |